Market Place
Sourcing Support
LENZ Announces Completion of Merger with Graphite Bio
21 Mar 2024 //
BUSINESSWIRE
Graphite Bio Declares Dividend In Connection with Proposed Merger with Lenz
08 Mar 2024 //
BUSINESSWIRE
Graphite Bio co-founder debuts Treg cell therapy startup with $75M
17 Jan 2024 //
ENDPTS
Graphite founder takes drug to Kamau Therapeutics for a second chance: #ASH23
11 Dec 2023 //
ENDPTS
Graphite Bio divests gene editing pipeline to newly-formed biotech
08 Dec 2023 //
ENDPTS
Graphite hands Nasdaq spot to presbyopia biotech Lenz as PhIII readouts loom
15 Nov 2023 //
ENDPTS
Graphite Bio Announces Departure of Chief Financial Officer
23 Jun 2023 //
BUSINESSWIRE
Graphite Bio to Reduce Workforce by 50%, Explores Strategic Alternatives
23 Feb 2023 //
BUSINESSWIRE
Beam hopes to sidestep sickle cell peers with gene editing
10 Jan 2023 //
FIERCEBIOTECH
Graphite halts sickle cell trial over effect on first patient
06 Jan 2023 //
FIERCE BIOTECH
Graphite Bio pauses early-stage blood disease therapy trial
06 Jan 2023 //
REUTERS
Graphite Announces Voluntary Pause of Phase 1/2 CEDAR Study of nula-cel
05 Jan 2023 //
BUSINESSWIRE
Graphite Bio Presents Preclinical Data for Novel Sequencing Method
11 Dec 2022 //
BUSINESSWIRE
Graphite Bio Announces Participation in Evercore Annual HealthCONx Conference
21 Nov 2022 //
BUSINESSWIRE
Graphite Bio Reports Recent Business Progress and 3Q 2022 Financial Results
09 Nov 2022 //
BUSINESSWIRE
Graphite Bio doses first subject in Phase I/II sickle cell disease trial
12 Aug 2022 //
CLINICALTRIALSARENA
Graphite Bio Doses First Patient with Investigational Editing Therapy GPH101
11 Aug 2022 //
BUSINESSWIRE
Graphite Bio begins SCD cell therapy trial
11 Aug 2022 //
ENDPOINTS NEWS
Graphite Bio Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Graphite Bio Doses First Patient with Gene Editing Therapy GPH101
11 Aug 2022 //
BUSINESSWIRE
Graphite Bio debuts corporate brand campaign with ‘Cure’ aspirations
28 Jul 2022 //
ENDPTS
Graphite Bio Announces Participation in Jefferies Healthcare Conference
01 Jun 2022 //
BUSINESSWIRE
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102
16 May 2022 //
BUSINESSWIRE
Graphite Bio Announces Participation in Upcoming Cowen Conference
03 Mar 2022 //
PRESS RELEASE
Graphite Bio Appoints Alethia Young as Chief Financial Officer
02 Mar 2022 //
PRESS RELEASE
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating GPH101 in SCD
11 Dec 2021 //
BUSINESSWIRE
Graphite Bio Enrolls 1st Patient in Phase 1/2 Trial of GPH101 for SCD
17 Nov 2021 //
BUSINESSWIRE
Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 ASH
04 Nov 2021 //
BIOSPACE
Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease
12 Oct 2021 //
BUSINESSWIRE
Graphite Bio Presents Preclinical Data Supporting GPH101
12 Oct 2021 //
BUSINESSWIRE
Graphite Bio Announces Participation in Upcoming September Investor Conferences
30 Aug 2021 //
BUSINESSWIRE
Graphite Bio Reports Business Progress and Second Quarter 2021 Financial Results
12 Aug 2021 //
BUSINESSWIRE
Graphite Bio leads this week`s IPO squad
26 Jun 2021 //
ENDPTS
Graphite grabs $238M IPO to advance sickle cell treatment
25 Jun 2021 //
FIERCEBIOTECH
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline
15 Mar 2021 //
BUSINESSWIRE
Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191
13 Jan 2021 //
BUSINESSWIRE
Graphite Bio Receives IND Clearance to Initiate Trial for Next-Generation
14 Dec 2020 //
BUSINESSWIRE
Next-gen gene editing: Graphite Bio launches with $45m funding
01 Oct 2020 //
PHARMACEUTICAL TECHNOLOGY
Next-gen gene editing: Graphite Bio launches with $45m funding
30 Sep 2020 //
PHARMACEUTICAL TECHNOLOGY
Next-gen gene editing: Graphite Bio launches with $45m funding
29 Sep 2020 //
PHARMACEUTICAL TECHNOLOGY
